c-MYB and DMTF1 in Cancer

References

• Beug H, von Kirchbach A, Döderlein G, Conscience JF, Graf T. Chicken hematopoietic cells transformed by seven strains of defective avian leukemia viruses display three distinct phenotypes of differentiation. Cell. 1979;18(2):375–390. doi:10.1016/0092-8674(79)90057-6.
   PubMed Web of Science ®Google Scholar
• Anderson SM, Chen JH. In vitro translation of avian myeloblastosis virus RNA. J Virol. 1981;40(1):107–117.
   PubMed Web of Science ®Google Scholar
• Wu Y, Duesberg P. Avian erythroblastosis virus E26: only one (myb) of two cell-derived coding regions is necessary for oncogenicity. Proc Natl Acad Sci USA. 1994;91(9):4039–4043.
   PubMed Web of Science ®Google Scholar
• Zorbas M, Sicurella C, Bertoncello I, Venter D, Ellis S, Mucenski ML, Ramsay RG. c-Myb is critical for murine colon development. Oncogene. 1999;18(42):5821–5830. doi:10.1038/sj.onc.1202971.
   PubMed Web of Science ®Google Scholar
• Shin DH, Lee HW, Jeon GS, Lee HY, Lee KH, Cho SS. Constitutive expression of c-myb mRNA in the adult rat brain. Brain Res. 2001;892(1):203–207.
   PubMed Web of Science ®Google Scholar
• Pelicci PG, Lanfrancone L, Brathwaite MD, Wolman SR, Dalla-Favera R. Amplification of the c-myb oncogene in a case of human acute myelogenous leukemia. Science. 1984;2241117–1121.
   PubMed Web of Science ®Google Scholar
• Poenitz N, Simon-Ackermann J, Gratchev A, Qadoumi M, Klemke C-D, Stadler R, Kremer A, Radenhausen M, Henke U, Assaf C, et al. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma. Dermatology (Basel). 2005;211(2):84–92.
   PubMed Web of Science ®Google Scholar
• Clappier E, Cuccuini W, Kalota A, Crinquette A, Cayuela J-M, Dik WA, Langerak AW, Montpellier B, Nadel B, Walrafen P, et al. The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood. 2007;110(4):1251–1261.
   PubMed Web of Science ®Google Scholar
• Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F, Mentens N, Beverloo HB, Pieters R, Speleman F, et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet. 2007;39(5):593–595.
   PubMed Web of Science ®Google Scholar
• O'Rourke JP, Ness SA. Alternative RNA splicing produces multiple forms of c-Myb with unique transcriptional activities. Mol Cell Biol. 2008;282091–2101. doi:10.1128/MCB.01870-07.
   PubMed Web of Science ®Google Scholar
• Murati A, Gervais C, Carbuccia N, Finetti P, Cervera N, Adélaïde J, Struski S, Lippert E, Mugneret F, Tigaud I, et al. Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases. Leukemia. 2009;23(1):85–94. doi:10.1038/leu.2008.257.
   PubMed Web of Science ®Google Scholar
• Zhao H, Kalota A, Jin S, Gewirtz AM. The c-myb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells. Blood. 2009;113(3):505–516.
   PubMed Web of Science ®Google Scholar
• Zhou YE, O'Rourke JP, Edwards JS, Ness SA. Single molecule analysis of c-myb alternative splicing reveals novel classifiers for precursor B-ALL. PLoS One. 2011;6(8):e22880. doi:10.1371/journal.pone.0022880.
   PubMed Web of Science ®Google Scholar
• Nakano K, Uchimaru K, Utsunomiya A, Yamaguchi K, Watanabe T. Dysregulation of c-Myb Pathway by Aberrant Expression of Proto-oncogene MYB Provides the Basis for Malignancy in Adult T-cell Leukemia/lymphoma Cells. Clin Cancer Res. 2016;22(23):5915–5928. doi:10.1158/1078-0432.CCR-15-1739.
   PubMed Web of Science ®Google Scholar
• Kauraniemi P, Hedenfalk I, Persson K, Duggan DJ, Tanner M, Johannsson O, Olsson H, Trent JM, Isola J, Borg A. MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res. 2000;60(19):5323–5328.
   PubMed Web of Science ®Google Scholar
• Nicolau M, Levine AJ, Carlsson G. Topology based data analysis identifies a subgroup of breast cancers with a unique mutational profile and excellent survival. Proc Natl Acad Sci USA. 2011;108(17):7265–7270. doi:10.1073/pnas.1102826108.
   PubMed Web of Science ®Google Scholar
• Persson M, Andren Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA. 2009;106(44):18740–18744.
   PubMed Web of Science ®Google Scholar
• Rajan N, Andersson MK, Sinclair N, Fehr A, Hodgson K, Lord CJ, Kazakov DV, Vanecek T, Ashworth A, Stenman G. Overexpression of MYB drives proliferation of CYLD-defective cylindroma cells. J Pathol. 2016;239(2):197–205.
   PubMed Web of Science ®Google Scholar
• Guérin M, Sheng ZM, Andrieu N, Riou G. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene. 1990;5131–135.
   PubMed Web of Science ®Google Scholar
• Gudas JM, Klein RC, Oka M, Cowan KH. Posttranscriptional regulation of the c-myb proto-oncogene in estrogen receptor-positive breast cancer cells. Clin Cancer Res. 1995;1235–243.
   PubMed Web of Science ®Google Scholar
• Torelli G, Venturelli D, Colo A, Zanni C, Selleri L, Moretti L, et al. Expression of c-myb protooncogene and other cell cycle-related genes in normal and neoplastic human colonic mucosa. Cancer Res. 1987;475266–5269.
   PubMed Web of Science ®Google Scholar
• Ramsay RG, Thompson MA, Hayman JA, Reid G, Gonda TJ, Whitehead RH. Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa. Cell Growth Differ. 1992;3723–730.
   PubMedGoogle Scholar
• Biroccio A, Benassi B, D’Agnano I, D’Angelo C, Buglioni S, Mottolese M, Ricciotti A, Citro G, Cosimelli M, Ramsay RG, et al. c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am J Pathol. 2001;158(4):1289–1299. doi:10.1016/S0002-9440(10)64080-1.
   PubMed Web of Science ®Google Scholar
• Abaza MS, Al-Attiyah RJ, Al-Saffar AM, Al-Sawan SM, Moussa NM. Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells. Tumor Biol. 2003;24(5):241–257. doi:10.1159/000076139.
   PubMedGoogle Scholar
• Hugo H, Cures A, Suraweera N, Drabsch Y, Purcell D, Mantamadiotis T, Phillips W, Dobrovic A, Zupi G, Gonda TJ, et al. Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers. Genes Chromosomes Cancer. 2006;45(12):1143–1154.
   PubMed Web of Science ®Google Scholar
• Wallrapp C, Müller-Pillasch F, Solinas-Toldo S, Lichter P, Friess H, Büchler M, Fink T, Adler G, Gress TM. Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene. Cancer Res. 1997;57(15):3135–3139.
   PubMed Web of Science ®Google Scholar
• Yang K, He M, Cai Z, Ni C, Deng J, Ta N, Xu J, Zheng J. A decrease in miR-150 regulates the malignancy of pancreatic cancer by targeting c-Myb and MUC4. Pancreas. 2015;44(3):370–379.
   PubMed Web of Science ®Google Scholar
• Welter C, Henn W, Theisinger B, Fischer H, Zang KD, Blin N. The cellular myb oncogene is amplified, rearranged and activated in human glioblastoma cell lines. Cancer Lett. 1990;52(1):57–62. doi:10.1016/0304-3835(90)90077-B.
   PubMed Web of Science ®Google Scholar
• Patt S, Thiel G, Maas S, Lozanova T, Prosenc N, Cervos-Navarro J, et al. Chromosomal changes and correspondingly altered proto-oncogene expression in human gliomas. Value of combined cytogenetic and molecular genetic analysis. Anticancer Res. 1993;13113–118.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Pan Y, Joshi K, Purohit D, Hu B, Demir H, Mazumder S, Okabe S, Yamori T, Viapiano M, et al. Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb. Clin Cancer Res. 2012;18(5):1268–1280.
   PubMed Web of Science ®Google Scholar
• Dasgupta P, Linnenbach AJ, Giaccia AJ, Stamato TD, Reddy EP. Molecular cloning of the breakpoint region on chromosome 6 in cutaneous malignant melanoma: evidence for deletion in the c-myb locus and translocation of a segment of chromosome 12. Oncogene. 1989;4(10):1201–1205.
   PubMed Web of Science ®Google Scholar
• Walker MJ, Silliman E, Dayton MA, Lang JC. The expression of C-myb in human metastatic melanoma cell lines and specimens. Anticancer Res. 1998;18(2A):1129–1135.
   PubMed Web of Science ®Google Scholar
• Morey AL, Murali R, McCarthy SW, Mann GJ, Scolyer RA. Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation. Pathology. 2009;41(4):383–387. doi:10.1080/00313020902915875.
   PubMed Web of Science ®Google Scholar
• Mitani Y, Li J, Rao PH, Zhao YJ, Bell D, Lippman SM, et al. Comprehensive analysis of the MYB-NF1B gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance. Clin. Cancer Res. 2010;164722–4731. doi:10.1158/1078-0432.CCR-10-0463.
   Web of Science ®Google Scholar
• Lu H, Wang Y, Huang Y, Shi H, Xue Q, Yang S, He S, Wang H. Expression and prognostic role of c-Myb as a novel cell cycle protein in esophageal squamous cell carcinoma. Clin Transl Oncol. 2013;15(10):796–801.
   PubMed Web of Science ®Google Scholar
• Xing D, Bakhsh S, Melnyk N, Isacson C, Ho J, Huntsman DG, Gilks CB, Ronnett BM, Horlings HM. Frequent NFIB-associated Gene Rearrangement in Adenoid Cystic Carcinoma of the Vulva. Int J Gynecol Pathol. 2017;36(3):289–293.
   PubMed Web of Science ®Google Scholar
• von Holstein SL, Fehr A, Persson M, Therkildsen MH, Prause JU, Heegaard S, Stenman G. Adenoid cystic carcinoma of the lacrimal gland: MYB gene activation, genomic imbalances, and clinical characteristics. Ophthalmology. 2013;120(10):2130–2138.
   PubMed Web of Science ®Google Scholar
• Stenman G, Andersson MK, Andrén Y. New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer. Cell Cycle. 2010;9(15):2986–2995.
   PubMed Web of Science ®Google Scholar
• Barroga CF, Pham H, Kaushansky K. Thrombopoietin regulates c-Myb expression by modulating micro RNA 150 expression. Exp Hematol. 2008;36(12):1585–1592.
   PubMed Web of Science ®Google Scholar
• Clappier E, Soulier J. t(6;7)(q23;q34). Atlas Genet Cytogenet Oncol Haematol. 2008;12248–249.
   Google Scholar
• Dastugue N, Duchayne E, Kuhlein E, Rubie H, Demur C, Aurich J, et al. Acute basophilic leukaemia and translocation t(X;6)(p11;q23). Br J Haematol. 1997;9170–176. doi:10.1046/j.1365-2141.1997.1562968.x.
   Google Scholar
• Quelen C, Lippert E, Struski S, Demur C, Soler G, Prade N, Delabesse E, Broccardo C, Dastugue N, Mahon F-X, et al. Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants. Blood. 2011;117(21):5719–5722.
   PubMed Web of Science ®Google Scholar
• de Almeida-Pinto YD, Costa SFDS, Bab DA, Altemani A, Vargas PA, Abreu LG, et al. t(6;9)(MYB-NFIB) in head and neck adenoid cystic carcinoma: A systematic review with meta-analysis. Oral Dis. 2018; Sep 30. doi:10.1111/odi.12984. [Epub ahead of print] Review.
   PubMedGoogle Scholar
• Blobel GA. CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood. 2000;95745–755.
   PubMed Web of Science ®Google Scholar
• Ramsay RG. c-Myb a stem-progenitor cell regulator in multiple tissue compartments. [Database]. Growth Factors. 2005;23(4):253–261.
   PubMed Web of Science ®Google Scholar
• Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, Lee TI, Young RA. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153(2):307–319.
   PubMed Web of Science ®Google Scholar
• Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, Hoke HA, Young RA. Super-enhancers in the control of cell identity and disease. Cell. 2013;155(4):934–947.
   PubMed Web of Science ®Google Scholar
• Calabretta B, Sims RB, Valtieri M, Caracciolo D, Szczylik C, Venturelli D, Ratajczak M, Beran M, Gewirtz AM. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. Proc Natl Acad Sci USA. 1991;88(6):2351–2355. doi:10.1073/pnas.88.6.2351.
   PubMed Web of Science ®Google Scholar
• Tamm I, Wagner M. Antisense therapy in clinical oncology: preclinical and clinical experiences. MB. 2006;33(3):221–238. doi:10.1385/MB:33:3:221.
   Google Scholar
• Millikin D, Meese E, Vogelstein B, Witkowski C, Trent J. Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma. Cancer Res. 1991;51(20):5449–5453.
   PubMed Web of Science ®Google Scholar
• Ponti G, Ruini C, Massi D, Pellacani G, Tomasi A, Paglierani M, Loschi P, Seidenari S. Fluorescence in-situ hybridization and dermoscopy in the assessment of controversial melanocytic tumors. Melanoma Res. 2013;23(6):474–480. doi:10.1097/CMR.0000000000000020.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ness SA. Myb proteins: angels and demons in normal and transformed cells. Front Biosci (Landmark Ed). 2011;161109–1131.
   PubMed Web of Science ®Google Scholar
• Nomura N, Takahashi M, Matsui M, Ishii S, Date T, Sasamoto S, Ishizaki R. Isolation of human cDNA clones of myb-related genes, A-myb and B-myb. Nucleic Acids Res. 1988;16(23):11075–11089.
   PubMed Web of Science ®Google Scholar
• Trauth K, Mutschler B, Jenkins NA, Gilbert DJ, Copeland NG, Klempnauer KH. Mouse A-myb encodes a trans-activator and is expressed in mitotically active cells of the developing central nervous system, adult testis and B lymphocytes. Embo J. 1994;13(24):5994–6005. doi:10.1002/j.1460-2075.1994.tb06945.x.
   PubMed Web of Science ®Google Scholar
• Golay J, Luppi M, Songia S, Palvarini C, Lombardi L, Aiello A, Delia D, Lam K, Crawford DH, Biondi A, et al. Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, sIg + B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias. Blood. 1996;87(5):1900–1911.
   PubMed Web of Science ®Google Scholar
• Lipsick JS, Manak J, Mitiku N, Chen CK, Fogarty P, Guthrie E. Functional evolution of the Myb oncogene family. Blood Cells Mol Dis. 2001;27(2):456–458.
   PubMed Web of Science ®Google Scholar
• Hirai H, Sherr CJ. Interaction of D-type cyclins with a novel myb-like transcription factor, DMP1. Mol Cell Biol. 1996;16(11):6457–6567.
   PubMed Web of Science ®Google Scholar
• Inoue K, Sherr CJ. Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins through a cyclin-dependent-kinase-independent mechanism. Mol Cell Biol. 1998;18(3):1590–1600.
   PubMed Web of Science ®Google Scholar
• Inoue K, Sherr CJ, Shapiro LH. Regulation of the CD13/Aminopeptidase N gene by DMP1, a transcription factor antagonized by D-type cyclins. J Biol Chem. 1998;273(44):29188–29194.
   PubMed Web of Science ®Google Scholar
• Bodner SM, Naeve CW, Rakestraw KM, Jones BG, Valentine VA, Valentine MB, Luthardt FW, Willman CL, Raimondi SC, Downing JR, et al. Cloning and chromosomal localization of the gene encoding human cyclin D-binding Myb-like protein (hDMP1). Gene. 1999;229(1-2):223–228.
   PubMed Web of Science ®Google Scholar
• Inoue K, Roussel MF, Sherr CJ. Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci USA. 1999;96(7):3993–3998.
   PubMed Web of Science ®Google Scholar
• Inoue K, Wen R, Rehg JE, Adachi M, Cleveland JL, Roussel MF, et al. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Genes Dev. 2000;141797–1809.
   PubMed Web of Science ®Google Scholar
• Inoue K, Zindy F, Randle DH, Rehg JE, Sherr CJ. Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev. 2001;15(22):2934–2939. doi:10.1101/gad.929901.
   PubMed Web of Science ®Google Scholar
• Sreeramaneni R, Chaudhry A, McMahon M, Sherr CJ, Inoue K. Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor. Mol Cell Biol. 2005;25(1):220–232. doi:10.1128/MCB.25.1.220-232.2005.
   PubMed Web of Science ®Google Scholar
• Mallakin A, Taneja P, Matise LA, Willingham MC, Inoue K. Expression of Dmp1 in specific differentiated, nonproliferating cells and its repression by E2Fs. Oncogene. 2006;25(59):7703–7713. doi:10.1038/sj.onc.1209750.
   PubMed Web of Science ®Google Scholar
• Taneja P, Mallakin A, Matise LA, Frazier DP, Choudhary M, Inoue K. Repression of Dmp1 and Arf transcription by anthracyclins: critical roles of the NF-kappaB subunit p65. Oncogene. 2007;26(53):7457–7466.
   PubMed Web of Science ®Google Scholar
• Mallakin A, Sugiyama T, Taneja P, Matise LA, Frazier DP, Choudhary M, Hawkins GA, D'Agostino RB, Willingham MC, Inoue K. Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer. Cancer Cell. 2007;12(4):381–394.
   PubMed Web of Science ®Google Scholar
• Taneja P, Maglic D, Kai F, Sugiyama T, Kendig RD, Frazier DP, Willingham MC, Inoue K. Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development. Cancer Res. 2010;70(22):9084–9094.
   PubMed Web of Science ®Google Scholar
• Mallakin A, Sugiyama T, Kai F, Taneja P, Kendig RD, Frazier DP, et al. The Arf-inducing transcription factor Dmp1 encodes transcriptional activator of amphiregulin, thrombospondin-1, JunB and Egr1. Int J Cancer. 2010;1261403–1416. doi:10.1002/ijc.24938.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Srour EF. Regulation of murine hematopoietic stem cell quiescence by Dmtf1. Blood. 2011;118(25):6562–6571.
   PubMed Web of Science ®Google Scholar
• Maglic D, Zhu S, Fry EA, Taneja P, Kai F, Kendig RD, Sugiyama T, Miller LD, Willingham MC, Inoue K. Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer. Oncogene. 2013;32(35):4120–4129.
   PubMed Web of Science ®Google Scholar
• Zhu S, Mott RT, Fry EA, Taneja P, Kulik G, Sui G, Inoue K. Cooperation between Dmp1 loss and cyclin D1 overexpression in breast cancer. Am J Pathol. 2013;183(4):1339–1350.
   PubMed Web of Science ®Google Scholar
• Fry EA, Taneja P, Maglic D, Zhu S, Sui G, Inoue K. Dmp1α inhibits HER2/neu-induced mammary tumorigenesis. PLoS One. 2013;8(10):e77870
   PubMed Web of Science ®Google Scholar
• Frazier DP, Kendig RD, Kai F, Maglic D, Sugiyama T, Morgan RL, Fry EA, Lagedrost SJ, Sui G, Inoue K, et al. Dmp1 physically interacts with p53 and positively regulates p53’s stabilization, nuclear localization, and function. Cancer Res. 2012;72(7):1740–1750. doi:10.1158/0008-5472.CAN-11-2410.
   PubMed Web of Science ®Google Scholar
• Kendig RD, Kai F, Fry EA, Inoue K. Stabilization of the p53-DNA complex by the nuclear protein Dmp1α. Cancer Invest. 2017;35(5):301–312.
   PubMed Web of Science ®Google Scholar
• Inoue K, Mallakin A, Frazier DP. Dmp1 and tumor suppression. Oncogene. 2007;26(30):4329–4335.
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Frazier DP, Taneja P, Morgan RL, Willingham MC, Inoue K. The role of Dmp1 and its future in lung cancer diagnostics. Expert Rev Mol Diagn. 2008;8(4):435–448.
   PubMed Web of Science ®Google Scholar
• Inoue K, Fry EA, Frazier DP. Transcription factors that interact with p53 and Mdm2. Int J Cancer. 2016;138(7):1577–1585.
   PubMed Web of Science ®Google Scholar
• Inoue K, Fry EA. Aberrant expression of Cyclin D1 in cancer. Sign Transduct Insights. 2015;41–13.
   PubMedGoogle Scholar
• Inoue K, Fry EA. Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer. Int J Cancer. 2016;139(1):33–41.
   PubMed Web of Science ®Google Scholar
• Fry EA, Taneja P, Inoue K. Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu. Int J Cancer. 2017;140(3):495–503.
   PubMed Web of Science ®Google Scholar
• Fry EA, Taneja P, Inoue K. Clinical applications of mouse models for breast cancer engaging HER2/neu. Integr Cancer Sci Ther. 2016;3593–603.
   PubMedGoogle Scholar
• Inoue K, Fry EA. Haplo-insufficient tumor suppressor genes. A book chapter in ‘Advances in Medicine and Biology’, Nova Science Publishers, Inc. Volume118, Chapter 6, 83–122, 2017.
   Google Scholar
• Sherr CJ, Bertwistle D, DEN Besten W, Kuo M-L, Sugimoto M, Tago K, Williams RT, Zindy F, Roussel MF. p53-Dependent and -independent functions of the Arf tumor suppressor. Cold Spring Harb Symp Quant Biol. 2005;70129–137.
   PubMedGoogle Scholar
• Maggi LB, Winkeler CL, Miceli AP, Apicelli AJ, Brady SN, Kuchenreuther MJ, Weber JD. ARF tumor suppression in the nucleolus. Biochim Biophys Acta. 2014;1842(6):831–839.
   PubMed Web of Science ®Google Scholar
• Inoue K, Fry EA. Aberrant expression of ARF in human cancer - a new biomarker? Tumor and Microenvironment. in press.
   Google Scholar
• Inoue K, Fry EA. Aberrant expression of p16INK4a in human cancer - a new biomarker? Cancer Rep Rev. 2018; Mar2(2): doi:10.15761/CRR.1000145. Epub 2018 Jan 15.
   Google Scholar
• Maglic D, Stovall DB, Cline JM, Fry EA, Mallakin A, Taneja P, Caudell DL, Willingham MC, Sui G, Inoue K. DMP1β, a splice isoform of the tumour suppressor DMP1 locus, induces proliferation and progression of breast cancer. J Pathol. 2015;236(1):90–102.
   PubMed Web of Science ®Google Scholar
• Tschan MP, Federzoni EA, Haimovici A, Britschgi C, Moser BA, Jin J, Reddy VA, Sheeter DA, Fischer KM, Sun P, et al. Human DMTF1β antagonizes DMTF1α regulation of the p14(ARF) tumor suppressor and promotes cellular proliferation. Biochim Biophys Acta. 2015;1849(9):1198–1208.
   PubMed Web of Science ®Google Scholar
• Inoue K, Fry EA. Novel biomarkers for breast cancer. Biomark Cancer. 2016;81–18.
   Google Scholar
• Tschan MP, Gullberg U, Shan D, Torbett BE, Fey MF, Tobler A. The hDMP1 tumor suppressor is a new WT1 target in myeloid leukemias. Leukemia. 2008;22(5):1087–1090.
   PubMed Web of Science ®Google Scholar
• Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994; 843071–3079.
   PubMed Web of Science ®Google Scholar
• Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, Kudoh T, Akiyama T, Murakami A, Maekawa T. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood. 1996;87(7):2878–2884.
   PubMed Web of Science ®Google Scholar
• Inoue K, Ogawa H, Yamagami T, Soma T, Tani T, Tatekawa T, et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood. 1996;882267–2278.
   PubMed Web of Science ®Google Scholar
• Tamaki H, Ogawa H, Inoue K, Soma T, Yamagami T, Miyake S, Oka Y, Oji Y, Tatekawa T, Tsuboi A, et al. Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia. Blood. 1996;88(11):4396–4398.
   PubMed Web of Science ®Google Scholar
• Ogawa H, Tsuboi A, Oji Y, Tamaki H, Soma T, Inoue K, Sugiyama H. Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogeneic bone marrow transplantation: importance of the monitoring of minimal residual disease by WT1 assay. Bone Marrow Transplant. 1998;21(5):525–527. doi:10.1038/sj.bmt.1701123.
   PubMed Web of Science ®Google Scholar
• Tamaki H, Ogawa H, Ohyashiki K, Ohyashiki JH, Iwama H, Inoue K, Soma T, Oka Y, Tatekawa T, Oji Y, et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia. 1999;13(3):393–399.
   PubMed Web of Science ®Google Scholar
• Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, Miyake S, Tamaki H, Oji Y, Yamagami T, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 1997;89(4):1405–1412.
   PubMed Web of Science ®Google Scholar
• Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T, et al. Wilms’ tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood. 1998;912969–2976.
   PubMed Web of Science ®Google Scholar
• Inoue K, Sugiyama T, Taneja P, Morgan RL, Frazier DP. Emerging roles of DMP1 in lung cancer. Cancer Res. 2008;68(12):4487–4490.
   PubMed Web of Science ®Google Scholar
• Inoue K, Fry EA. Alterations of p63 and p73 in human cancers in ‘Mutant p53 and MDM2 in cancer’. Editors: Swati Palit Deb & Sumitra Deb. Springer, NY. Chapter 2: 17-40, 2014. Subcell Biochem. 2014;8517–40.
   PubMedGoogle Scholar
• Inoue K, Fry EA. Aberrant splicing of estrogen receptor, HER2, and CD44 in breast cancer. Genetics & Epigenetics. 2015;719–32.
   PubMed Web of Science ®Google Scholar
• Sveen A, Kilpinen S, Ruusulehto A, Lothe RA, Skotheim RI. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene. 2016;35(19):2413–2427. doi:10.1038/onc.2015.318.
   PubMed Web of Science ®Google Scholar
• Luz FA, Brígido PC, Moraes AS, Silva MJ. Aberrant Splicing in Cancer: Mediators of Malignant Progression through an Imperfect Splice Program Shift. Oncology. 2017;92(1):3–13. doi:10.1159/000450650.
   PubMed Web of Science ®Google Scholar
• Klempnauer KH, Gonda TJ, Bishop JM. Nucleotide sequence of the retroviral leukemia gene v-myb and its cellular progenitor c-myb: the architecture of a transduced oncogene. Cell. 1982;31(2):453–463. doi:10.1016/0092-8674(82)90138-6.
   PubMed Web of Science ®Google Scholar
• Gonda TJ, Bishop JM. Structure and transcription of the cellular homolog (c-myb) of the avian myeloblastosis virus transforming gene (v-myb). J Virol. 1983;46(1):212–220.
   PubMed Web of Science ®Google Scholar
• Franchini G, Wong-Staal F, Baluda MA, Lengel C, Tronick SR. Structural organization and expression of human DNA sequences related to the transforming gene of avian myeloblastosis virus. Proc Natl Acad Sci USA. 1983;80(24):7385–7389. doi:10.1073/pnas.80.24.7385.
   PubMed Web of Science ®Google Scholar
• Gonda TJ, Gough NM, Dunn AR, de Blaquiere J. Nucleotide sequence of cDNA clones of the murine myb proto-oncogene. Embo J. 1985;4(8):2003–2008.
   PubMed Web of Science ®Google Scholar
• Oh IH, Reddy EP. The myb gene family in cell growth, differentiation and apoptosis. Oncogene. 1999;18(19):3017–3033.
   PubMed Web of Science ®Google Scholar
• Mucenski ML, McLain K, Kier AB, Swerdlow SH, Schreiner CM, Miller TA, Pietryga DW, Scott WJ, Jr, Potter SS. A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell. 1991;65(4):677–689.
   PubMed Web of Science ®Google Scholar
• Emambokus N, Vegiopoulos A, Harman B, Jenkinson E, Anderson G, Frampton J. Progression through key stages of haemopoiesis is dependent on distinct threshold levels of c-Myb. Embo J. 2003;22(17):4478–4488.
   PubMed Web of Science ®Google Scholar
• Lieu YK, Reddy EP. Conditional c-myb knockout in adult hematopoietic stem cells leads to loss of self-renewal due to impaired proliferation and accelerated differentiation. Proc Natl Acad Sci USA. 2009;106(51):21689–21694.
   PubMed Web of Science ®Google Scholar
• Lieu YK1, Reddy EP. Impaired adult myeloid progenitor CMP and GMP cell function in conditional c-myb-knockout mice. Cell Cycle. 2012;11(18):3504–3512.
   PubMed Web of Science ®Google Scholar
• Malaterre J, Carpinelli M, Ernst M, Alexander W, Cooke M, Sutton S, Dworkin S, Heath JK, Frampton J, McArthur G, et al. c-Myb is required for progenitor cell homeostasis in colonic crypts. Proc Natl Acad Sci USA. 2007;104(10):3829–3834.
   PubMed Web of Science ®Google Scholar
• Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood. 1996;87(6):2162–2170.
   PubMed Web of Science ®Google Scholar
• Levin J, Cocault L, Demerens C, Challier C, Pauchard M, Caen J, Souyri M. Thrombocytopenic c-mpl(-/-) mice can produce a normal level of platelets after administration of 5-fluorouracil: the effect of age on the response. Blood. 2001;98(4):1019–1027.
   PubMed Web of Science ®Google Scholar
• Carpinelli MR, Hilton DJ, Metcalf D, Antonchuk JL, Hyland CD, Mifsud SL, Di Rago L, Hilton AA, Willson TA, Roberts AW, et al. Suppressor screen in Mpl-/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. Proc Natl Acad Sci USA. 2004;101(17):6553–6558.
   PubMed Web of Science ®Google Scholar
• Sandberg ML, Sutton SE, Pletcher MT, Wiltshire T, Tarantino LM, Hogenesch JB, Cooke MP. c-Myb and p300 regulate hematopoietic stem cell proliferation and differentiation. Dev Cell. 2005;8(2):153–166.
   PubMed Web of Science ®Google Scholar
• Dalla-Favera R, Franchini G, Martinotti S, Wong-Staal F, Gallo RC, Croce CM. Chromosomal assignment of the human homologues of feline sarcoma virus and avian myeloblastosis virus onc genes. Proc Natl Acad Sci USA. 1982;79(15):4714–4717.
   PubMed Web of Science ®Google Scholar
• Harper ME, Franchini G, Love J, Simon MI, Gallo RC, Wong-Staal F. Chromosomal sublocalization of human c-myb and c-fes cellular onc genes. Nature. 1983;304(5922):169–171.
   PubMed Web of Science ®Google Scholar
• Winqvist R, Knuutila S, Leprince D, Stehelin D, Alitalo K. Mapping of amplified c-myb oncogene, sister chromatid exchanges, and karyotypic analysis of the COLO 205 colon carcinoma cell line. Cancer Genet Cytogenet. 1985;18(3):251–264.
   PubMedGoogle Scholar
• Janssen JW, Vernole P, de Boer PA, Oosterhuis JW, Collard JG. Sublocalization of c-myb to 6q21-q23 by in situ hybridization and c-myb expression in a human teratocarcinoma with 6q rearrangements. Cytogenet Cell Genet. 1986;41(3):129–235.
   PubMedGoogle Scholar
• Kolomietz E, Meyn MS, Pandita A, Squire JA. The role of Alu repeat clusters as mediators of recurrent chromosomal aberrations in tumors. Genes Chromosom Cancer. 2002;35(2):97–112. doi:10.1002/gcc.10111.
   PubMed Web of Science ®Google Scholar
• O'Neil J, Tchinda J, Gutierrez A, Moreau L, Maser RS, Wong K-K, Li W, McKenna K, Liu XS, Feng B, et al. Alu elements mediate MYB gene tandem duplication in human T-ALL. J Exp Med. 2007;204(13):3059–3066.
   PubMed Web of Science ®Google Scholar
• Barletta C, Pelicci PG, Kenyon LC, Smith SD, Dalla-Favera R. Relationship between the c-myb locus and the 6q-chromosomal aberration in leukemias and lymphomas. Science. 1987;235(4792):1064–1067.
   PubMed Web of Science ®Google Scholar
• Ohyashiki K, Ohyashiki JH, Kinniburgh AJ, Toyama K, Ito H, Minowada J, Sandberg AA. myb oncogene in human hematopoietic neoplasia with 6q- anomaly. Cancer Genet Cytogenet. 1988;33(1):83–92.
   PubMedGoogle Scholar
• Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV, Shi J, Weissmueller S, Fellman C, Taylor MJ, et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 2011;25(15):1628–1640. doi:10.1101/gad.17269211.
   PubMed Web of Science ®Google Scholar
• Moody SE, Sarkisian CJ, Hahn KT, Gunther EJ, Pickup S, Dugan KD, Innocent N, Cardiff RD, Schnall MD, Chodosh LA, et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell. 2002;2(6):451–461. doi:10.1016/S1535-6108(02)00212-X.
   PubMed Web of Science ®Google Scholar
• Yeh ES, Yang TW, Jung JJ, Gardner HP, Cardiff RD, Chodosh LA. Hunk is required for HER2/neu-induced mammary tumorigenesis. J Clin Invest. 2011;121(3):866–879.
   PubMed Web of Science ®Google Scholar
• Zhu N, Chen M, Eng R, DeJong J, Sinha AU, Rahnamay NF, Koche R, Al-Shahrour F, Minehart JC, Chen C-W, et al. MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. J Clin Invest. 2016;126(3):997–1011.
   PubMed Web of Science ®Google Scholar
• Sroczynska P, Cruickshank VA, Bukowski J-P, Miyagi S, Bagger FO, Walfridsson J, Schuster MB, Porse B, Helin K. shRNA screening identifies JMJD1C as being required for leukemia maintenance. Blood. 2014;123(12):1870–1882.
   PubMed Web of Science ®Google Scholar
• Gewirtz AM. Myb targeted therapeutics for the treatment of human malignancies. Oncogene. 1999;18(19):3056–3062. doi:10.1038/sj.onc.1202785.
   PubMed Web of Science ®Google Scholar
• Lidonnici MR, Corradini F, Waldron T, Bender TP, Calabretta B. Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis. Blood. 2008;111(9):4771–4779.
   PubMed Web of Science ®Google Scholar
• Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986;233(4760):212–214.
   PubMed Web of Science ®Google Scholar
• Luger SM, O'Brien SG, Ratajczak J, Ratajczak MZ, Mick R, Stadtmauer EA, et al. Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. Blood. 2002;99(4):1150–1158. doi:10.1182/blood.V99.4.1150.
   PubMed Web of Science ®Google Scholar
• Kalota A, Karabon L, Swider CR, Viazovkina E, Elzagheid M, Damha MJ, et al. 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (2'F-ANA) modified oligonucleotides (ON) effect highly efficient, and persistent, gene silencing. Nucleic Acids Res. 2006;34(2):451–461. doi:10.1093/nar/gkj455.
   PubMed Web of Science ®Google Scholar
• Kakizuka A, Miller WH, Umesono K, Warrell RP, Frankel SR, Murty VVVS, Dmitrovsky E, Evans RM. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991;66(4):663–674. doi:10.1016/0092-8674(91)90112-C.
   PubMed Web of Science ®Google Scholar
• Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood. 1992;801825–1831.
   PubMed Web of Science ®Google Scholar
• Uttarkar S, Dassé E, Coulibaly A, Steinmann S, Jakobs A, Schomburg C, Trentmann A, Jose J, Schlenke P, Berdel WE, et al. Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction. Blood. 2016;127(9):1173–1182.
   PubMed Web of Science ®Google Scholar
• Uttarkar S, Piontek T, Dukare S, Schomburg C, Schlenke P, Berdel WE, Müller-Tidow C, Schmidt TJ, Klempnauer K-H. Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells. Mol Cancer Ther. 2016;15(12):2905–2915. doi:10.1158/1535-7163.MCT-16-0185.
   PubMed Web of Science ®Google Scholar
• Coulibaly A, Haas A, Steinmann S, Jakobs A, Schmidt TJ, Klempnauer KH. The natural anti-tumor compound Celastrol targets a Myb-C/EBPβ-p300 transcriptional module implicated in myeloid gene expression. PLoS One. 2018;13(2):e0190934. doi:10.1371/journal.pone.0190934.
   PubMed Web of Science ®Google Scholar
• Jakobs A, Steinmann S, Henrich SM, Schmidt TJ, Klempnauer KH. Helenalin Acetate, a Natural Sesquiterpene Lactone with Anti-inflammatory and Anti-cancer Activity, Disrupts the Cooperation of CCAAT Box/Enhancer-binding Protein β (C/EBPβ) and Co-activator p300. J Biol Chem. 2016;291(50):26098–26108.
   PubMed Web of Science ®Google Scholar
• Uttarkar S, Frampton J, Klempnauer KH. Targeting the transcription factor Myb by small-molecule inhibitors. Exp Hematol. 2017;4731–35.
   PubMed Web of Science ®Google Scholar
• Mink S, Haenig B, Klempnauer KH. Interaction and functional collaboration of p300 and C/EBPbeta. Mol Cell Biol. 1997;17(11):6609–6617.
   PubMed Web of Science ®Google Scholar
• Roe JS, Mercan F, Rivera K, Pappin DJ, Vakoc CR. BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia. Mol Cell. 2015;58(6):1028–1039. doi:10.1016/j.molcel.2015.04.011.
   PubMed Web of Science ®Google Scholar
• Mitani Y, Liu B, Rao PH, Borra VJ, Zafereo M, Weber RS, Kies M, Lozano G, Futreal PA, Caulin C, et al. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations. Clin Cancer Res. 2016;22(3):725–733.
   PubMed Web of Science ®Google Scholar
• Wysocki PT, Izumchenko E, Meir J, Ha PK, Sidransky D, Brait M. Adenoid cystic carcinoma: emerging role of translocations and gene fusions. Oncotarget. 2016;766239–66625.
   PubMedGoogle Scholar
• Gonda TJ, Ramsay RG. Adenoid Cystic Carcinoma Can Be Driven by MYB or MYBL1 Rearrangements: New Insights into MYB and Tumor Biology. Cancer Discov. 2016;6(2):125–127.
   PubMed Web of Science ®Google Scholar
• Brayer KJ, Frerich CA, Kang H, Ness SA. Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma. Cancer Discov. 2016;6(2):176–187. doi:10.1158/2159-8290.CD-15-0859.
   PubMed Web of Science ®Google Scholar
• Persson M, Andrén Y, Moskaluk CA, Frierson HF, Cooke SL, Futreal PA, Kling T, Nelander S, Nordkvist A, Persson F, et al. Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma. Genes Chromosom Cancer. 2012;51(8):805–817. doi:10.1002/gcc.21965.
   PubMed Web of Science ®Google Scholar
• Drier Y, Cotton MJ, Williamson KE, Gillespie SM, Ryan RJH, Kluk MJ, Carey CD, Rodig SJ, Sholl LM, Afrogheh AH, et al. An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nat Genet. 2016;48(3):265–272.
   PubMed Web of Science ®Google Scholar
• Bender TP, Thompson CB, Kuehl WM. Differential expression of c-myb mRNA in murine B lymphomas by a block to transcription elongation. Science. 1987;237(4821):1473–1476.
   PubMed Web of Science ®Google Scholar
• Thompson MA, Flegg R, Westin EH, Ramsay RG. Microsatellite deletions in the c-myb transcriptional attenuator region associated with over-expression in colon tumour cell lines. Oncogene. 1997;14(14):1715–1723.
   PubMed Web of Science ®Google Scholar
• Drabsch YI, Hugo H, Zhang R, Dowhan DH, Miao YR, Gewirtz AM, Barry SC, Ramsay RG, Gonda TJ. Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells. Proc Natl Acad Sci USA. 2007;104(34):13762–13767.
   Google Scholar
• Jin W, Liu Y, Chen L, Zhu H, Di G-h, Ling H, Wu J, Shao Z-M. Involvement of MyoD and c-myb in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene. Breast Cancer Res Treat. 2011;125(3):699–713. doi:10.1007/s10549-010-0876-1.
   PubMed Web of Science ®Google Scholar
• Gasco M, Yulug IG, Crook T. TP53 mutations in familial breast cancer: functional aspects. Hum Mutat. 2003;21(3):301–306.
   PubMed Web of Science ®Google Scholar
• Masood S. Prognostic/predictive factors in breast cancer. Clin Lab Med. 2005;25(4):809–825,viii.
   PubMed Web of Science ®Google Scholar
• Taneja P, Maglic D, Kai F, Zhu S, Kendig RD, Fry EA, et al. Classical and novel molecular prognostic markers for human breast cancer and their clinical significance. Clin Med Oncol. 2010;415–34.
   Google Scholar
• Wiesner FG, Magener A, Fasching PA, Wesse J, Bani MR, Rauh C, Jud S, Schrauder M, Loehberg CR, Beckmann MW, et al. Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast. 2009;18(2):135–141. doi:10.1016/j.breast.2009.02.009.
   PubMed Web of Science ®Google Scholar
• Baron V, Adamson ED, Calogero A, Ragona G, Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther. 2006;13(2):115–124. doi:10.1038/sj.cgt.7700896.
   PubMed Web of Science ®Google Scholar
• Silva J, Domínguez G, Silva JM, García JM, Gallego I, Corbacho C, Provencio M, España P, Bonilla F. Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. Oncogene. 2001;20(33):4586–4590.
   PubMed Web of Science ®Google Scholar
• Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Löning T. Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat. 2001;67(1):61–70.
   PubMed Web of Science ®Google Scholar
• Silva J, Silva JM, Domínguez G, García JM, Cantos B, Rodríguez R, Larrondo FJ, Provencio M, España P, Bonilla F. Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J Pathol. 2003;199(3):289–297.
   PubMed Web of Science ®Google Scholar
• Ladanyi M. Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer. 2005;49 (Suppl 1):S95–S98.
   PubMed Web of Science ®Google Scholar
• Li B, Rosen JM, McMenamin-Balano J, Muller WJ, Perkins AS. neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice. Mol Cell Biol. 1997;17(6):3155–3163. doi:10.1128/MCB.17.6.3155.
   PubMed Web of Science ®Google Scholar
• Taneja P, Frazier DP, Kendig RD, Maglic D, Sugiyama T, Kai F, Taneja NK, Inoue K. MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Rev Mol Diagn. 2009;9(5):423–440.
   PubMed Web of Science ®Google Scholar
• D'Amico M, Wu K, Di Vizio D, Reutens AT, Stahl M, Fu M, Albanese C, Russell RG, Muller WJ, White M, et al. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis. Cancer Res. 2003;63(12):3395–3402.
   PubMed Web of Science ®Google Scholar
• Taneja P, Zhu S, Maglic D, Fry EA, Kendig RD, Inoue K. Transgenic and knockout mice models to reveal the functions of tumor suppressor genes. Clin Med Insights Oncol. 2011;5235–257.
   PubMedGoogle Scholar
• Inoue K, Fry EA, Taneja P. Recent progress in mouse models for tumor suppressor genes and its implications in human cancer. Clin Med Oncol. 2013;7103–122.
   Google Scholar
• George OL, Ness SA. Situational awareness: regulation of the myb transcription factor in differentiation, the cell cycle and oncogenesis. Cancers (Basel). 2014;6(4):2049–2071. doi:10.3390/cancers6042049.
   PubMed Web of Science ®Google Scholar
• Fu SL, Lipsick JS. FAETL motif required for leukemic transformation by v-Myb. J Virol. 1996;70(8):5600–5610.
   PubMed Web of Science ®Google Scholar
• Dash AB, Orrico FC, Ness SA. The EVES motif mediates both intermolecular and intramolecular regulation of c-Myb. Genes Dev. 1996;10(15):1858–1869.
   PubMed Web of Science ®Google Scholar